Predicted protein targets (top 5)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | HTR3A | P46098 | 12/20 | 0.76 |
| ▸ | HTR4 | Q13639 | 12/20 | 0.76 |
| ▸ | PARP1 | P09874 | 7/20 | 0.56 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.56 |
| ▸ | PKM | P14618 | 1/20 | 0.56 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL828330 | 0.95 | HTR4 (0.85) | HTR3AHTR4PARP1KDM4EPKM | |
| SCHEMBL828769 | 0.88 | HTR3A (0.62) | HTR3AHTR4PARP1KDM4EPKM | |
| Felcisetrag SCHEMBL390795 | 0.86 | HTR4 (1.00) | HTR3AHTR4 | |
| Felcisetrag SCHEMBL4361880 | 0.85 | HTR4 (0.98) | HTR3AHTR4 | |
| SCHEMBL8090284 | 0.85 | HTR3A (0.77) | HTR3AHTR4PARP1 | |
| SCHEMBL828678 | 0.83 | HTR4 (0.67) | HTR3AHTR4PARP1KDM4EPKM | |
| SCHEMBL828734 | 0.83 | HTR4 (0.84) | HTR3AHTR4PARP1 | |
| SCHEMBL1724211 | 0.82 | HTR4 (0.87) | HTR3AHTR4PARP1 | |
| SCHEMBL29397140 | 0.81 | HTR4 (0.68) | HTR3AHTR4PARP1 | |
| SCHEMBL828936 | 0.81 | HTR4 (0.68) | HTR3AHTR4PARP1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 27 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20220274957-A1 | BENZIMIDAZOLE-CARBOXAMIDE COMPOUNDS AS 5-HT4 RECEPTOR AGONISTS | THERAVANCE BIOPHARMA R&D IP, LLC (US) | 2022-09-01 | — | — | US | disclosed |
| US-11254655-B2 | Benzimidazole-carboxamide compounds as 5-HT4 receptor agonists | THERAVANCE BIOPHARMA R&D IP, LLC (US) | 2022-02-22 | — | — | US | disclosed |
| US-20200283408-A1 | BENZIMIDAZOLE-CARBOXAMIDE COMPOUNDS AS 5-HT4 RECEPTOR AGONISTS | THERAVANCE BIOPHARMA R&D IP, LLC (US) | 2020-09-10 | — | — | US | disclosed |
| US-10696656-B2 | Benzimidazole-carboxamide compounds as 5-HT4 receptor agonists | THERAVANCE BIOPHARMA R&D IP, LLC (US) | 2020-06-30 | — | — | US | disclosed |
| US-20190152951-A1 | BENZIMIDAZOLE-CARBOXAMIDE COMPOUNDS AS 5-HT4 RECEPTOR AGONISTS | THERAVANCE BIOPHARMA R&D IP, LLC (US) | 2019-05-23 | — | — | US | disclosed |
| US-10233172-B2 | Benzimidazole-carboxamide compounds as 5-HT4 receptor agonists | THERAVANCE BIOPHARMA R&D IP, LLC (US) | 2019-03-19 | — | — | US | disclosed |
| US-20180237420-A1 | BENZIMIDAZOLE-CARBOXAMIDE COMPOUNDS AS 5-HT4 RECEPTOR AGONISTS | THERAVANCE BIOPHARMA R&D IP, LLC (US) | 2018-08-23 | — | — | US | disclosed |
| US-9975877-B2 | Benzimidazole-carboxamide compounds as 5-HT4 receptor agonists | THERAVANCE BIOPHARMA R&D IP, LLC (US) | 2018-05-22 | — | — | US | disclosed |
| US-20170081313-A1 | BENZIMIDAZOLE-CARBOXAMIDE COMPOUNDS AS 5-HT4 RECEPTOR AGONISTS | THERAVANCE BIOPHARMA R&D IP, LLC (US) | 2017-03-23 | — | — | US | disclosed |
| US-9428489-B2 | Benzimidazole-carboxamide compounds as 5-HT4 receptor agonists | THERAVANCE BIOPHARMA R&D IP, LLC (US) | 2016-08-30 | — | — | US | disclosed |
| US-7897775-B2 | Crystalline form of a benzimidazole-carboxamide medicinal compound | THERAVANCE, INC. (US) | 2011-03-01 | — | — | US | disclosed |
| US-20100249186-A1 | BENZIMIDAZOLE-CARBOXAMIDE COMPOUNDS AS 5-HT4 RECEPTOR AGONISTS | THERAVANCE BIOPHARMA R&D IP, LLC | 2010-09-30 | — | — | US | disclosed |
| US-7759363-B2 | Benzimidazole-carboxamide compounds as 5-HT4, receptor agonists | THERAVANCE, INC. (US) | 2010-07-20 | — | — | US | disclosed |
| US-20100029946-A1 | CRYSTALLINE FORM OF A BENZIMIDAZOLE-CARBOXAMIDE MEDICINAL COMPOUND | THERAVANCE, INC. (US) | 2010-02-04 | — | — | US | disclosed |
| US-7622587-B2 | Crystalline form of a benzimidazole-carboxamide medicinal compound | THERAVANCE, INC. (US) | 2009-11-24 | — | — | US | disclosed |
| US-20090209582-A1 | Benzimidazole-carboxamide compounds as 5-ht4 receptor agonists | THERAVANCE BIOPHARMA R&D IP, LLC | 2009-08-20 | — | — | US | disclosed |
| US-20070244157-A1 | Crystalline form of a benzimidazole-carboxamide medicinal compound | THERAVANCE BIOPHARMA R&D IP, LLC | 2007-10-18 | — | — | US | disclosed |
| US-7256294-B2 | Crystalline form of a benzimidazole-carboxamide medicinal compound | THERAVANCE, INC. (US) | 2007-08-14 | — | — | US | disclosed |
| US-20060270854-A1 | Crystalline form of a benzimidazole-carboxamide medicinal compound | THERAVANCE, INC. | 2006-11-30 | — | — | US | disclosed |
| US-20060270652-A1 | Benzimidazole-carboxamide compounds as 5-HT4, receptor agonists | THERAVANCE, INC. | 2006-11-30 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (14 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20070244157-A1 | Crystalline form of a benzimidazole-carboxamide medicinal compound | HTR4, HTR5A, HTR1A | HTR3A 19/4885HTR4 1/4885PARP1 1058/4885 |
| US-10233172-B2 | Benzimidazole-carboxamide compounds as 5-HT4 receptor agonists | HTR4, HTR1A, HTR5A | HTR3A 18/4885HTR4 1/4885PARP1 1181/4885 |
| US-20180237420-A1 | BENZIMIDAZOLE-CARBOXAMIDE COMPOUNDS AS 5-HT4 RECEPTOR AGONISTS | HTR4, HTR1A, HTR5A | HTR3A 18/4885HTR4 1/4885PARP1 1181/4885 |
| US-20200283408-A1 | BENZIMIDAZOLE-CARBOXAMIDE COMPOUNDS AS 5-HT4 RECEPTOR AGONISTS | HTR4, HTR1A, HTR5A | HTR3A 18/4885HTR4 1/4885PARP1 1181/4885 |
| US-20090209582-A1 | Benzimidazole-carboxamide compounds as 5-ht4 receptor agonists | HTR4, HTR1A, HTR5A | HTR3A 19/4885HTR4 1/4885PARP1 1125/4885 |
| US-20100249186-A1 | BENZIMIDAZOLE-CARBOXAMIDE COMPOUNDS AS 5-HT4 RECEPTOR AGONISTS | HTR4, HTR1A, HTR5A | HTR3A 18/4885HTR4 1/4885PARP1 1181/4885 |
| US-11254655-B2 | Benzimidazole-carboxamide compounds as 5-HT4 receptor agonists | HTR4, HTR1A, HTR5A | HTR3A 18/4885HTR4 1/4885PARP1 1181/4885 |
| US-10696656-B2 | Benzimidazole-carboxamide compounds as 5-HT4 receptor agonists | HTR4, HTR1A, HTR5A | HTR3A 18/4885HTR4 1/4885PARP1 1181/4885 |
| US-20220274957-A1 | BENZIMIDAZOLE-CARBOXAMIDE COMPOUNDS AS 5-HT4 RECEPTOR AGONISTS | HTR4, HTR1A, HTR5A | HTR3A 18/4885HTR4 1/4885PARP1 1181/4885 |
| US-20060270652-A1 | Benzimidazole-carboxamide compounds as 5-HT4, receptor agonists | HTR4, HTR1A, HTR5A | HTR3A 18/4885HTR4 1/4885PARP1 1267/4885 |
| US-20100029946-A1 | CRYSTALLINE FORM OF A BENZIMIDAZOLE-CARBOXAMIDE MEDICINAL COMPOUND | HTR4, HTR5A, HTR1A | HTR3A 19/4885HTR4 1/4885PARP1 1058/4885 |
| US-20190152951-A1 | BENZIMIDAZOLE-CARBOXAMIDE COMPOUNDS AS 5-HT4 RECEPTOR AGONISTS | HTR4, HTR1A, HTR5A | HTR3A 18/4885HTR4 1/4885PARP1 1181/4885 |
| US-20170081313-A1 | BENZIMIDAZOLE-CARBOXAMIDE COMPOUNDS AS 5-HT4 RECEPTOR AGONISTS | HTR4, HTR1A, HTR5A | HTR3A 18/4885HTR4 1/4885PARP1 1181/4885 |
| US-20060270854-A1 | Crystalline form of a benzimidazole-carboxamide medicinal compound | HTR4, HTR5A, HTR1A | HTR3A 19/4885HTR4 1/4885PARP1 1058/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.